# Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout

> **NCT01078389** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 314 (actual)

## Conditions studied

- Joint Damage

## Interventions

- **DRUG:** Febuxostat
- **DRUG:** Placebo for Febuxostat

## Key facts

- **NCT ID:** NCT01078389
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2014-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01078389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01078389, "Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01078389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*